相似文献
1
Tumefactive demyelination presenting during bevacizumab treatment.
BMJ Case Rep. 2015 Dec 16;2015:bcr2015212173. doi: 10.1136/bcr-2015-212173.
2
Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Int Ophthalmol. 2017 Apr;37(2):325-332. doi: 10.1007/s10792-016-0241-4. Epub 2016 May 28.
3
Using intravitreal bevacizumab (Avastin) - Indian Scenario.
Indian J Ophthalmol. 2017 Jul;65(7):545-548. doi: 10.4103/ijo.IJO_431_17.
4
[Intravitreal bevacizumab for choroidal neovascularization associated with Best's disease].
Arch Soc Esp Oftalmol. 2014 Oct;89(10):405-7. doi: 10.1016/j.oftal.2013.07.002. Epub 2014 Feb 5.
5
Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
Digit J Ophthalmol. 2016 Jun 30;22(2):46-53. doi: 10.5693/djo.01.2014.01.004. eCollection 2016.
6
FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Retina. 2015 Dec;35(12):2457-68. doi: 10.1097/IAE.0000000000000610.
7
Intravitreal bevacizumab for idiopathic choroidal neovascularization.
J AAPOS. 2009 Jun;13(3):296-8. doi: 10.1016/j.jaapos.2008.12.003. Epub 2009 Mar 14.
8
Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.
Int Ophthalmol. 2015 Jun;35(3):441-4. doi: 10.1007/s10792-015-0059-5. Epub 2015 Mar 12.
9
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.
10
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.
Br J Ophthalmol. 2006 Nov;90(11):1344-9. doi: 10.1136/bjo.2006.099598. Epub 2006 Jul 19.
引用本文的文献
1
B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.
Pharmaceuticals (Basel). 2021 Jan 6;14(1):37. doi: 10.3390/ph14010037.
2
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
BMC Cancer. 2018 Jan 24;18(1):95. doi: 10.1186/s12885-018-3997-2.
本文引用的文献
1
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
J Neurol Sci. 2014 Sep 15;344(1-2):193-7. doi: 10.1016/j.jns.2014.06.013. Epub 2014 Jun 17.
2
Tumefactive multiple sclerosis and fingolimod.
J Neurol Sci. 2014 Sep 15;344(1-2):1-2. doi: 10.1016/j.jns.2014.06.022. Epub 2014 Jun 24.
3
Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.
J Neuropathol Exp Neurol. 2012 Nov;71(11):983-99. doi: 10.1097/NEN.0b013e3182724831.
4
Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.
Breast J. 2012 Sep;18(5):502-3. doi: 10.1111/j.1524-4741.2012.01293.x. Epub 2012 Aug 15.
5
Sera from neuromyelitis optica patients disrupt the blood-brain barrier.
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):288-97. doi: 10.1136/jnnp-2011-300434. Epub 2011 Nov 19.
6
The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.
PLoS One. 2011 May 6;6(5):e19138. doi: 10.1371/journal.pone.0019138.
7
An unusual optic disc neovascularization in a case of intermediate uveitis associated with multiple sclerosis.
Eur J Ophthalmol. 2008 Nov-Dec;18(6):1020-2. doi: 10.1177/112067210801800629.
Zotero 插件